Could one year of treatment be enough for advanced melanoma?
NCT ID NCT07376317
First seen Feb 02, 2026 · Last updated May 13, 2026 · Updated 15 times
Summary
This study tests whether giving the immunotherapy drug pembrolizumab for one year instead of the usual two years is just as effective for people with advanced melanoma that has spread. The trial involves 29 participants in Brazil's public health system. Researchers will track how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICESP
São Paulo, São Paulo, 01246000, Brazil
Conditions
Explore the condition pages connected to this study.